Latib

Imatinib, the active ingredient in Latib, is a tyrosine kinase inhibitor presented as a tablet for oral use. It is employed in the treatment of chronic myeloid leukemia, Philadelphia chromosome‑positive acute lymphoblastic leukemia, and gastrointestinal stromal tumor, targeting the underlying molecular drivers of these cancers and is indicated for patients with these specific genetic abnormalities.

GNH USA supplies Latib as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance across global markets.

Imatinib acts on BCR‑ABL and related tyrosine‑kinase driven pathways, providing therapeutic benefit in several malignancies. - Chronic myeloid leukemia: achieves disease control and prolongs survival. - Philadelphia chromosome‑positive acute lymphoblastic leukemia: induces remission and improves overall survival. - Gastrointestinal stromal tumor: reduces tumor growth and delays disease progression.

Imatinib may cause a range of adverse reactions, varying from mild to severe. Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Edema: peripheral swelling, often in the ankles. - Muscle cramps: painful involuntary contractions. - Fatigue: persistent tiredness. - Diarrhea: loose stools. - Rash: mild skin irritation. Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or liver injury. - Severe neutropenia: marked reduction in white blood cells. - Cardiac failure: reduced heart function, especially in patients with pre‑existing disease. - Pulmonary hypertension: increased pressure in lung arteries. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hemorrhage: abnormal bleeding events.

When prescribing imatinib, several safety considerations should be observed. - Pregnancy: category D, use only if benefits outweigh risks. - Breastfeeding: not recommended; advise against nursing during treatment. - Hepatic impairment: assess liver function and adjust therapy as needed. - Cardiac function: monitor for signs of heart failure or reduced ejection fraction. - Drug interactions: review concomitant medications for CYP3A4 inhibitors or inducers. - Store at below 25°C: keep in the original packaging, protect from moisture and light.

Imatinib interacts with several medicines that can alter its efficacy or safety profile. Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase imatinib exposure. - Macrolide antibiotics (e.g., clarithromycin): may raise plasma levels. - Antifungal azoles (e.g., voriconazole): potentiate toxicity. - Grapefruit juice: can significantly elevate drug concentrations. - Concomitant use with other BCR‑ABL inhibitors: risk of additive toxicity. Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): reduce imatinib effectiveness. - Warfarin: may require INR monitoring. - Diuretics (e.g., furosemide): monitor electrolytes. - Antacids containing aluminum or magnesium: may affect absorption. - Vaccines (live attenuated): assess timing relative to therapy.